Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Berinert Claims Another Part Of The HAE Orphan Market, But May Leave Room

Executive Summary

FDA's approval of CSL Behring's Berinert for treatment of acute attacks of hereditary angioedema specifically mentions only two types of attacks. By approving the C1 esterase inhibitor with a targeted indication, the agency could be leaving open a window in the orphan exclusivity for another approval

You may also be interested in...

CSL Behring Launches Co-Pay Assistance Program For Berinert

Program provides commercially insured patients with up to $12,000 a year in eligible expenses for C1 esterase inhibitor Berinert, used to treat the rare disease hereditary angioedema.

Different Endpoints Drive HAE Drugs On Road To Approval

With four drugs in the space, hereditary angioedema is an unusually well-served orphan disease. But the rare condition still has no clear path for efficacy assessment.

Shire Finally Able To Move Firazyr Forward

Shire reports positive phase III results for its HAE drug and may file a complete response in the next few months.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts